Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11544791 | 0.88 | ALDH1A1 (0.53) | NPC1L3MBTL1ACACBALDH1A1 | |
| SCHEMBL3650027 | 0.86 | ALDH1A1 (0.41) | APPACACBALDH1A1 | |
| SCHEMBL28747451 | 0.84 | VCP (0.46) | KMT2AMEN1NPC1RAB9AACACB | |
| SCHEMBL6553345 | 0.83 | CYP3A4 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9935172 | 0.83 | CA12 (0.50) | APPKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL17845127 | 0.82 | APP (0.57) | APPKMT2AMEN1NPC1POLB | |
| SCHEMBL853918 | 0.81 | FFAR1 (0.51) | NPC1L3MBTL1ALDH1A1 | |
| SCHEMBL852379 | 0.81 | L3MBTL1 (0.44) | KMT2ARAB9AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL2433672 | 0.81 | APP (0.45) | APPKMT2AMEN1NPC1RAB9A | |
| SCHEMBL2300644 | 0.81 | ACACB (0.44) | NPC1RAB9AL3MBTL1ACACBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425010-B8 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | JANSSEN PHARMACEUTICALS INC (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-1425010-B1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-1425010-A4 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | LU TIANBO | 2007-09-20 | — | — | US | disclosed |
| US-7241789-B2 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICAL, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050250771-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | disclosed |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-09-22 | — | — | US | disclosed |
| US-6855722-B2 | Substituted indoles and their use as integrin antagonists | DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| EP-1226108-A4 | DIARYL-ENYNES | NPS ALLELIX CORP (CA) | 2004-06-16 | — | — | EP | disclosed |
| EP-1425010-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6579987-B2 | Reducing an ester containing ene-yne conjugated, silane and aryl or heteroaryl functionality to an alcohol; bromination, amination, desilanation, coupling and deprotecting | NPS ALLELIX CORPORATION (CA) | 2003-06-17 | — | — | US | disclosed |
| US-20030092769-A1 | DIARYL-ENYNES | NPS ALLELIX CORPORATION (CA) | 2003-05-15 | — | — | US | disclosed |
| US-6525085-B2 | Treating neurological and neuropsychiatric disorders | NPS ALLELIX CORP. (CA) | 2003-02-25 | — | — | US | disclosed |
| US-20020169197-A1 | Diaryl-enynes | NPS ALLELIX CORP. | 2002-11-14 | — | — | US | disclosed |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002060438-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| EP-1226108-A1 | DIARYL-ENYNES | NPS Allelix Corp. (CA) | 2002-07-31 | — | — | EP | disclosed |
| US-6426364-B1 | NERVOUS SYSTEM OR PSYCHOLOGICAL DISORDERS | NPS ALLELIX CORP. (CA) | 2002-07-30 | — | — | US | disclosed |
| WO-2001032602-A1 | DIARYL-ENYNES | NPS ALLELIX CORP. (CA) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | ITGA5, ADGRE5, ITGAV | APP 1632/4885HDAC3 747/4885HDAC4 1286/4885 |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | APP 1616/4885HDAC3 924/4885HDAC4 1548/4885 |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGAL, ITGA5 | APP 2254/4885HDAC3 939/4885HDAC4 2015/4885 |
| US-20050250771-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | APP 1587/4885HDAC3 935/4885HDAC4 1674/4885 |
| US-20020169197-A1 | Diaryl-enynes | CBR3, CNR1, NR3C2 | APP 4065/4885HDAC3 92/4885HDAC4 2439/4885 |
| US-20030092769-A1 | DIARYL-ENYNES | CBR3, CNR1, CBR1 | APP 4068/4885HDAC3 97/4885HDAC4 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.